{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"If available, data on the use of medication affecting secondary hyperparathyroidism (those who received calcimimetics and calcium supplementation) in the 6 months leading up to paricalcitol treatment and during 6 months of paricalcitol treatment were also collected.","groups":[{"description":"Participants with chronic kidney disease (CKD) stage 5 receiving haemodialysis with a diagnosis of secondary hyperparathyroidism (SHPT)","id":"OG000","title":"End-stage Kidney Disease With Secondary Hyperparathyroidism"}],"populationDescription":"This outcome measure was not analyzed due to lack of data.","reportingStatus":"POSTED","timeFrame":"6 months prior to start of study through 6 months of treatment","title":"Country-Specific Data on the Usage of Medication Affecting Secondary Hyperparathyroidism","type":"SECONDARY"}